Bank Julius Baer & Co. Ltd, Zurich Seagen Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $87,520 - $98,785	457 Added 35.34%	1,750 $371,000
Q2 2023 Jul 24, 2023	BUY	$187.64 - $206.25 $242,618 - $266,681	1,293 New	1,293 $249,000
Q1 2023 May 11, 2023	SELL	$127.59 - $203.08 $34,194 - $54,425	-268 Reduced 16.31%	1,375 $278,000
Q4 2022 Jan 24, 2023	SELL	$117.37 - $139.17 $130,867 - $155,174	-1,115 Reduced 40.43%	1,643 $211,000
Q3 2022 Nov 04, 2022	BUY	$135.27 - $180.11 $151,367 - $201,543	1,119 Added 68.27%	2,758 $377,000

Q2 2022 Jul 22, 2022	BUY	$108.81 - $179.33 $178,339 - $293,921	1,639 New	1,639 $290,000
Q4 2021 Feb 15, 2022	SELL	$142.57 - $190.86 $131,164 - $175,591	-920 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $34,045 - $40,586	-239 Reduced 20.62%	920 $156,000
Q2 2021 Jul 23, 2021	SELL	$135.08 - $161.1 $18,776 - $22,392	-139 Reduced 10.71%	1,159 $183,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $23,239 - $32,245	-169 Reduced 11.52%	1,298 $180,000
Q4 2020 Feb 24, 2021	SELL	$164.63 - $211.93 $430,507 - $554,196	-2,615 Reduced 64.06%	1,467 $257,000
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $672,019 - $865,098	4,082 New	4,082 $257,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.